Cargando…

Dosing Cariprazine Within and Beyond Clinical Trials: Recommendations for the Treatment of Schizophrenia

Although the optimal dosing of an antipsychotic medication is known to be essential in the long-term management of schizophrenia, in case of novel drugs such as cariprazine, determining the right dosing strategy is not that simple. Without decades of experience with a particular compound, evidence r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rancans, Elmars, Dombi, Zsófia Borbála, Barabássy, Ágota
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8768837/ https://www.ncbi.nlm.nih.gov/pubmed/35069278 http://dx.doi.org/10.3389/fpsyt.2021.770234

Ejemplares similares

The effectiveness and safety of cariprazine in schizophrenia patients with negative symptoms and insufficient effectiveness of previous antipsychotic therapy: an observational study
por: Rancans, Elmars, et al.
Publicado: (2021)

Case report: Treatment-resistant schizophrenia with auto-aggressive compulsive behavior—Successful management with cariprazine
por: Renemane, Lubova, et al.
Publicado: (2023)

Successful high dose antipsychotic treatment with cariprazine in patients on the schizophrenia spectrum: Real-world evidence from a Spanish hospital setting
por: Galmes, Lluis Niell, et al.
Publicado: (2023)

Real-Life Clinical Experience With Cariprazine: A Systematic Review of Case Studies
por: Csehi, Réka, et al.
Publicado: (2022)

Cariprazine Safety in Adolescents and the Elderly: Analyses of Clinical Study Data
por: Szatmári, Balázs, et al.
Publicado: (2020)

Cariprazine in the Treatment of Bipolar Disorder: Within and Beyond Clinical Trials
por: Do, André, et al.
Publicado: (2021)

Editorial: Community series in novel antipsychotics within and beyond clinical trials: symptom-based treatment of psychiatric disorders with D3-D2 partial agonists, volume II
por: Falkai, Peter, et al.
Publicado: (2023)

The efficacy of cariprazine in chronic schizophrenia – post hoc analyses of phase II/III clinical trials
por: Falkai, P., et al.
Publicado: (2022)

Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety
por: Laszlovszky, István, et al.
Publicado: (2021)

Cariprazine’s efficacy in treating affective symptoms – pooled data from schizophrenia and bipolar depression trials
por: Mcintyre, R., et al.
Publicado: (2022)

Clinical Global Impression of Cariprazine in Negative Symptom Schizophrenia Patients: Comparison of clinical trial data vs. real-world evidence
por: Rancans, E., et al.
Publicado: (2023)

Case series: Cariprazine in early-onset schizophrenia
por: Ivanova, Elena, et al.
Publicado: (2023)

Benzodiazepine use during cariprazine treatment in acute schizophrenia
por: Correll, C., et al.
Publicado: (2022)

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies
por: Barabássy, Ágota, et al.
Publicado: (2021)

The effect of cariprazine on patient engagement: Post-hoc analysis of a phase 3 study in patients with predominant negative symptoms of schizophrenia
por: Laszlovszky, I., et al.
Publicado: (2021)

What Is the Minimum Clinically Important Change in Negative Symptoms of Schizophrenia? PANSS Based Post-hoc Analyses of a Phase III Clinical Trial
por: Czobor, Pál, et al.
Publicado: (2022)

Cariprazine's Potential in Improving Social Dysfunction in Patients With Schizophrenia: A Perspective
por: Morozov, Petr, et al.
Publicado: (2022)

Tolerability of cariprazine in the early stage of schizophrenia: A pooled, post-hoc analysis of 4 phase ii/iii double-blind placebo-controlled trials
por: Dombi, Z.B., et al.
Publicado: (2021)

Case Report: Cariprazine in a Patient With Schizophrenia, Substance Abuse, and Cognitive Dysfunction
por: Rodriguez Cruz, Jose, et al.
Publicado: (2021)

Implementing the Latvian Early Intervention Program (LAT-EIP) for Patients With Schizophrenia Spectrum First-Episode Psychosis: Study Protocol
por: Berze, Liene, et al.
Publicado: (2019)

Case Report: Cariprazine Efficacy in Young Patients Diagnosed With Schizophrenia With Predominantly Negative Symptoms
por: Vasiliu, Octavian
Publicado: (2021)

Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis
por: Durgam, Suresh, et al.
Publicado: (2017)

Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder
por: Vieta, Eduard, et al.
Publicado: (2019)

Cariprazine on Psychosis: Beyond Schizophrenia – A Case Series
por: Bajouco, Miguel, et al.
Publicado: (2022)

Relationship between the timing of relapse and plasma drug levels following discontinuation of cariprazine treatment in patients with schizophrenia: indirect comparison with other second-generation antipsychotics after treatment discontinuation
por: Correll, Christoph U, et al.
Publicado: (2019)

Validation of the generalized anxiety disorder scales (GAD-7 and GAD-2) in primary care settings in Latvia
por: Vrublevska, Jelena, et al.
Publicado: (2022)

Defining the therapeutic reference range for cariprazine
por: Kapás, M., et al.
Publicado: (2023)

Point prevalence and sex-specific associated factors of depression in Latvian general population
por: Vinogradova, Vineta Viktorija, et al.
Publicado: (2023)

Case Report: Long-Acting Oral Cariprazine
por: Dyrmishi, Emanuela, et al.
Publicado: (2022)

Reducing Addiction in Bipolar Disorder via Hacking the Dopaminergic System
por: Grunze, Heinz, et al.
Publicado: (2021)

Safety during polypharmacy: A post-hoc analysis examining the safety profile of cariprazine with other antipsychotics in the cross-titration phase
por: Vass, G., et al.
Publicado: (2021)

Cariprazine hydrochloride for schizophrenia
Publicado: (2021)

Improving Mood and Cognitive Symptoms in Huntington's Disease With Cariprazine Treatment
por: Molnar, Maria Judit, et al.
Publicado: (2022)

Brain Derived Neurotrophic Factor and Cognitive Dysfunction in the Schizophrenia-Bipolar Spectrum: A Systematic Review and Meta-Analysis
por: Dombi, Zsófia B., et al.
Publicado: (2022)

Cariprazine Use in Early Psychosis: Three Case Reports
por: Coentre, Ricardo, et al.
Publicado: (2021)

Association of Depression and Anxiety With the 10-Year Risk of Cardiovascular Mortality in a Primary Care Population of Latvia Using the SCORE System
por: Ivanovs, Rolands, et al.
Publicado: (2018)

Cariprazine in the treatment of schizophrenia: a proof-of-concept trial
por: Durgam, Suresh, et al.
Publicado: (2016)

Case report: Successful administration of cariprazine in a young, severely ill patient with recurrent relapses of schizophrenia and persistent negative symptoms
por: Vrublevska, Jelena
Publicado: (2023)

Assessment and Treatment of Negative Symptoms in Schizophrenia—A Regional Perspective
por: Bitter, Istvan, et al.
Publicado: (2022)

Treatment of Symptom Clusters in Schizophrenia, Bipolar Disorder and Major Depressive Disorder With the Dopamine D3/D2 Preferring Partial Agonist Cariprazine
por: Batinic, Borjanka, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8sktuio5js7afnderiotd99p5v